New Role Alert: Amit Patel named Head - Consumer Marketing Excellence, Cipla India Rx

Published On 2025-05-19 09:35 GMT   |   Update On 2025-05-19 09:37 GMT

Amit Patel has been elevated to Head - Consumer Marketing Excellence, Cipla India Rx.

Patel announced the development through a LinkedIn post, stating, "Excited to share that I’ve taken on a new role as Head – Consumer Marketing Excellence, Cipla India Rx. It’s been a meaningful journey leading clutter-breaking campaigns that have aimed to shift perception, build awareness, and create deeper connections between patients and therapy. Whether it was normalizing inhaler usage with Berok and Tuffies, breaking stigma around chronic conditions, or celebrating Cipla’s 90-year legacy in healthcare—each campaign has been rooted in purpose and insight."

Advertisement
"In this expanded role, I look forward to driving consumer marketing across therapeutic clusters—strengthening Cipla’s commitment to building patient-centric, insight-led narratives within the Rx ecosystem. This transition marks a new chapter that I believe will be both rewarding and full of learning, as we continue shaping impactful, purpose-driven ideas at scale. Here’s to new challenges, continued growth, and contributing to Cipla’s enduring legacy of caring for life," he added.

Patel, a consumer marketing evangelist and expert in Digital marketing and e-commerce, has 15 years of rich experience in India and International Markets - leading diverse teams, social media marketing, performance marketing and content marketing. 

He joined Cipla in 2022 as Director & Senior Head of Marketing - Metabolics and was later promoted to Director & Senior Marketing Head - Consumer Marketing - Respiratory. Before Cipla, 
he served Dabur International for more than 4 years. He also held roles at VLCC International LLC - Middle East and Africa, World Wide Fashion - Lemuda.com, Carbon Media Works, Capsicum Technologies, Karan Communications.

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.

Read also: Former Coca-Cola executive Punita Lal joins Lupin Board as Additional Director

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News